241 related articles for article (PubMed ID: 10932599)
1. Laboratory tests for neuroendocrine tumours.
Seregni E; Ferrari L; Stivanello M; Dogliotti L
Q J Nucl Med; 2000 Mar; 44(1):22-41. PubMed ID: 10932599
[TBL] [Abstract][Full Text] [Related]
2. The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours.
Ferrari L; Seregni E; Bajetta E; Martinetti A; Bombardieri E
Anticancer Res; 1999; 19(4C):3415-27. PubMed ID: 10629629
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
4. [Diagnosis of neuroendocrine tumours in the gastrointestinal tract].
Rehfeld JF; Friis-Hansen L; Gøtze JP; Hilsted L; Nielsen FC
Ugeskr Laeger; 2010 Oct; 172(43):2957-60. PubMed ID: 21040675
[TBL] [Abstract][Full Text] [Related]
5. New and emerging syndromes due to neuroendocrine tumors.
Vinik AI; Gonzales MR
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):19-63, vii. PubMed ID: 21349410
[TBL] [Abstract][Full Text] [Related]
6. An overview of the current diagnosis and recent developments in neuroendocrine tumours of the gastroenteropancreatic tract: the diagnostic approach.
Kuiper P; Verspaget HW; Overbeek LI; Biemond I; Lamers CB
Neth J Med; 2011 Jan; 69(1):14-20. PubMed ID: 21325696
[TBL] [Abstract][Full Text] [Related]
7. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
[TBL] [Abstract][Full Text] [Related]
9. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.
Ardill JE; O'Dorisio TM
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544
[TBL] [Abstract][Full Text] [Related]
10. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
11. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system].
Hörsch D; Sayeg Y; Bonnet R; Kaemmerer D; Presselt N; Baum RP
Pneumologie; 2012 Jan; 66(1):44-8. PubMed ID: 22250054
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview.
Oberg K; Astrup L; Eriksson B; Falkmer SE; Falkmer UG; Gustafsen J; Haglund C; Knigge U; Vatn MH; Välimäki M;
Acta Oncol; 2004; 43(7):617-25. PubMed ID: 15545182
[TBL] [Abstract][Full Text] [Related]
13. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours.
Janson ET; Sørbye H; Welin S; Federspiel B; Grønbaek H; Hellman P; Mathisen O; Mortensen J; Sundin A; Thiis-Evensen E; Välimäki MJ; Oberg K; Knigge U
Acta Oncol; 2010 Aug; 49(6):740-56. PubMed ID: 20553100
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
[TBL] [Abstract][Full Text] [Related]
15. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours.
Oberg K
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S17-25. PubMed ID: 22005113
[No Abstract] [Full Text] [Related]
16. Tumour biology and histopathology of neuroendocrine tumours.
Klöppel G
Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):15-31. PubMed ID: 17382263
[TBL] [Abstract][Full Text] [Related]
17. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
[TBL] [Abstract][Full Text] [Related]
18. [Neuroendocrine tumours of the upper gastrointestinal tract, characteristics and comparison of localization diagnostics].
Hyrdel R; Reznák I; Hyrdel P; Polácek H; Polácek H; Hladká M; Agouba SM; Janík J; Laca L
Vnitr Lek; 2011 Dec; 57(12):1017-24. PubMed ID: 22277035
[TBL] [Abstract][Full Text] [Related]
19. [Management of patients with non-functioning gastroentero-pancreatic neuroendocrine tumours].
Guarnieri A; Tirone A; Pallucca E; Testa M; Piccolomini A; Vuolo G; Savelli V; Di Cosmo L; Verre L; Carli AF
Chir Ital; 2006; 58(3):389-96. PubMed ID: 16845879
[TBL] [Abstract][Full Text] [Related]
20. Circulating markers for endocrine tumours of the gastroenteropancreatic tract.
Ardill JE
Ann Clin Biochem; 2008 Nov; 45(Pt 6):539-59. PubMed ID: 18941127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
